Phase III Study to Evaluate the Efficacy and Safety of AD-209
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.
Also called NCT06348576
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 280 participants
- Sponsor
- Registry
-
NCT06348576
-
- Other papers using this trial's data
- Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT06348576. Randomized; double masking; primary purpose treatment. Start 2024-05-20 (actual); primary completion 2025-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study to Evaluate the Efficacy and Safety of AD-209
- Condition
- Hypertension,Essential
- Intervention (Drug)
- AD-209
- Intervention (Drug)
- AD-2091
- Intervention (Drug)
- AD-209 Placebo
- Intervention (Drug)
- AD-2091 Placebo
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct06348576- Content hash
017d18553e1c356e032df7341d6b5cc7720dd1edd6ef777915b7b1697148ef5e